<div id="readability-page-1">New insider activity at Roivant Sciences ( (ROIV) ) has taken place on April 22, 2026.<h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul> President and Immunovant CEO Eric Venker has cashed out a substantial portion of his holdings in Roivant Sciences, selling 200,000 shares of the company’s stock in a transaction valued at $5,918,000. This insider sale highlights a significant move by a key executive with leadership roles at both Roivant and its affiliate Immunovant. Recent Updates on ROIV stock Roivant Sciences shares have been influenced by fresh analyst work and pipeline updates, with Piper Sandler assuming coverage after the stock’s roughly 190% rise over the past year, attributing strength to consistent positive data and execution in brepocitinib’s dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis programs. Analysts cite multi-indication, late-stage potential for brepocitinib—including new Phase 2b/3 development in lichen planopilaris and multiple pivotal readouts through 2026—as key to their revised expectations, while also factoring in the strategic refocus of Roivant’s autoimmune portfolio following failed Phase 3 results for batoclimab in thyroid eye disease and increased emphasis on next-generation asset IMVT-1402. Spark’s Take on ROIV Stock According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral. ROIV scores as a moderate-risk biotech: strong balance-sheet positioning and a constructive clinical/regulatory catalyst setup (including Priority Review) support the score, but persistent losses and ongoing cash burn weigh heavily. Technicals are neutral-to-slightly constructive, while valuation remains pressured due to negative earnings and no dividend support. To see Spark’s full report on ROIV stock, click here. More about Roivant Sciences YTD Price Performance: 34.98% Average Trading Volume: 5,959,517 Technical Sentiment Signal: Buy Current Market Cap: $20.81B</div>

ROIV

SBIO

On April 22, 2026, Eric Venker, President and CEO of Immunovant, sold 200,000 shares of Roivant Sciences (ROIV) for $5.9 million, indicating a significant insider move. Roivant's stock has risen approximately 190% over the past year, driven by positive data from its drug brepocitinib. Analysts from Piper Sandler have initiated coverage, highlighting the drug's potential across multiple indications. However, Spark's AI Analyst rates ROIV as Neutral due to ongoing losses and cash burn, despite a strong balance sheet and clinical catalysts. Roivant's current market cap is $20.81 billion, with a year-to-date price performance of 34.98%.

Top Biotech Insider Makes Bold Multi-Million Dollar Stock Move